Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tibotec, a pharmaceutical R&D company, has presented positive interim data from Phase IIa hepatitis study which demonstrated the antiviral activity of TMC435, an investigational protease inhibitor being developed by the company for the treatment of chronic hepatitis C virus infection.
Subscribe to our email newsletter
In interim findings from the first 28 days of treatment for the first cohort of 50 treatment naive hepatitis C virus plus (HCV+), genotype 1, patients (once daily dose of 25mg or 75mg TMC435 versus placebo), both doses showed dose-dependent antiviral activity.
TMC435 was administered in combination with PegIFNalpha-2a/RBV (triple therapy) for 28 days or as monotherapy for seven days and, thereafter, in combination with PegIFNalpha-2a/RBV (triple therapy) for three weeks. There were neither serious adverse events, nor grade 3 or 4 adverse events, related to TMC435 or any safety-related treatment discontinuations during this 28-day treatment period.
Roger Pomerantz, president of R&D at Tibotec, said: “Tibotec is committed to evaluating the safety and efficacy of TMC435 in clinical studies to determine its potential use in people with HCV. This is an important step in our mission of addressing treatment challenges of infectious diseases, including HCV, HIV and tuberculosis.”